- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Elaine Eisen, CORBETT WORLDWIDE HEALTHCARE COMMUNICATIONS
Virtually all pharmaceutical manufacturers have robust policies to place needed medicines in the hands of those who cannot afford to pay for them.
Elaine Eisen
PRESIDENT | CORBETT WORLDWIDE HEALTHCARE COMMUNICATIONS
Ironically, pharma has many patient assistance programs already firmly in place (established well before the current economic downturn). There is probably no other industry in America that has as many established initiatives to assure continuity of care for the customer.
Virtually all pharmaceutical manufacturers have robust policies to place needed medicines in the hands of those who cannot afford to pay for them. Although this is certainly not an exhaustive list, what follows is merely a portion of the programs that pharma has sponsored to safeguard the health of patients: the AstraZeneca Prescription Savings Program, the Merck Patient Assistance Program, the Alcon U.S. Patient Assistance Program, the Pfizer Friends Program, the Bristol-Myers Squibb Patient Assistance Foundation, the Procter & Gamble Pharmaceuticals Patient Assistance Program, and the Sanofi-Aventis Patient Assistance Program. Perhaps pharma needs to "toot its own horn" a little more loudly and recognize that those of us who work in the pharmaceutical industry are dedicated to extending and enhancing human life.
Elaine Eisen
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
